Abstract
Bimekizumab is a novel humanized bispecific monoclonal immunoglobulin G1 (IgG1) antibody that dually inhibits both IL-17A and IL-17F. Investigation of the pivotal role of IL-17A, and more recently, IL-17F, in the pathogenesis of psoriasis has underscored the utility of biologics targeting these cytokines in the treatment of the disease. Treatments include the anti-IL-17 biologics specifically targeted against IL-17A (secukinumab and ixekizumab) or its receptor (brodalumab). Recent clinical trials proved the efficacy and safety of bimekizumab in the treatment of moderate-to-severe plaque psoriasis and even showed it to be superior to other psoriasis biologic treatments in regards to efficacy and rapidity of response. These are important factors to consider when discussing treatment options with patients as psoriasis patients commonly desire fast-acting results. In this case, we describe clearance of moderate-to-severe plaque psoriasis within 72 hours of treatment with bimekizumab, one of the fastest reported clearance times in the medical literature. J Drugs Dermatol. 2024;23(8):694-696. doi:10.36849/JDD.8381.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
